HS
NKTR icon

HighVista Strategies’s Nektar Therapeutics NKTR Stock Holding History

HighVista Strategies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$608K Sell
8,708
-5,847
-40% -$428K 0.14% 141
2026
Q1 		$1.05M Buy
14,555
+2,806
+24% +$160K 0.29% 111
2025
Q4 		$497K Buy
+11,749
New +$658K 0.13% 142

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HighVista Strategies's NKTR Position: Q2 2026 in Review

HighVista Strategies reduced its Nektar Therapeutics (NKTR) stake by 40% in Q2 2026, selling an estimated $428K and leaving 8,708 shares worth $608K. The position accounts for 0.14% of the portfolio, ranked #141.

HighVista Strategies first reported a position in NKTR in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.05M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • HighVista Strategies held 8,708 shares of Nektar Therapeutics worth $608K as of Q2 2026.
  • HighVista Strategies sold 5,847 Nektar Therapeutics shares in Q2 2026, an estimated $428K.
  • Nektar Therapeutics made up 0.14% of HighVista Strategies's portfolio in Q2 2026, its #141 holding.
  • HighVista Strategies first reported a position in Nektar Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • HighVista Strategies's Nektar Therapeutics position peaked at $1.05M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.